It is with interest that the EAEPC has noted the results of the Matrix Insight study, commissioned by the European Commission and published on its website, recognising the positive role parallel trade may play in ensuring the availability of medicinal products in the EU and EEA.

More specifically, the study

  • identifies a number of EU states as examples where parallel trade brings down prices and improves availability of medicines.
  • identifies attempts to limit parallel trade, such as the imposition of quotas, as negatively impacting availability of medicines.
  • questions whether obligations for wholesalers may become less effective in ensuring supply due to changing distribution models.

To continue enhancing medicines availability, it is of utmost importance to uphold the EU’s principle of free movement of goods. This study shows that blaming free movement for medicines shortages is not only unjust, but may be counterproductive to alleviating such problems.

To access the study please follow the link below:

http://ec.europa.eu/health/files/committee/73meeting/73plus/study_report.pdf